IngentaConnect Mycobacterium kansasii in HIV patients: clarithromycin and antire...

Authors: Tompkins, J.C.¹; Witzig, R.S.¹

Source: The International Journal of Tuberculosis and Lung Disease, Volume 11, Number 3, March 2007 , pp. 331-337(7)

Publisher: International Union Against Tuberculosis and Lung Disease

Abstract:

SETTING: Charity Hospital New Orleans, Louisiana, USA.

OBJECTIVE: To define the differences between the pre-HAART (highly active anti-retroviral treatment) and HAART eras in patients co-infected with Mycobacterium kansasii and the human immunodeficiency virus (HIV).

DESIGN: A retrospective chart review revealed 82 patients with HIV and M. kansasii during the 6-year period from 1 July 1991 to 30 June 1997 (pre-HAART era), while the 6-year period from 1 July 1997 to 30 June 2003 (HAART era) revealed 55 cases.

RESULTS: Among all patients with M. kansasii and HIV, 47 (34%) had an additional, concurrent mycobacterial infection and two had triple mycobacterial species isolation. More patients (17/82, 21%) had disseminated mycobacterial disease in the pre-HAART era than in the HAART era (3/55, 5%; P = 0.045). Pre-HAART patients treated without clarithromycin (CLM) survived a median of 2 months vs. 10 months for pre-HAART patients treated with CLM (P = 0.05). Those treated without CLM had a median survival of 2 months in the pre-HAART era (n = 19) vs. 10.5 months in the HAART era (n = 12, P < 0.02).

CONCLUSION: CLM use in treatment of M. kansasii in HIV-co-infected patients is associated with significantly longer survival.

Keywords: Mycobacterium kansasii; HIV; HAART; atypical mycobacteria; NTM; CLM; AIDS; environmental mycobacteria

Document Type: Regular paper

Affiliations: 1: Infectious Diseases Section, Tulane University Health Sciences Center, New Orleans, Louisiana, USA

Mycobacterium kansasii in HIV patients: clarithromycin and antiretroviral effects